Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate

Lancet

Volumn 369, Issue 9577, 2007, Pages 1923-1924

  Nicholaou, Theo ^a   Wong, Rachel ^a   Davis, Ian D ^a  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

POLYSTYRENESULFONATE SODIUM; RASBURICASE; SUNITINIB;

CLINICAL FEATURE; CLINICAL TRIAL; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; KIDNEY CARCINOMA; LABORATORY TEST; LETTER; NEPHRECTOMY; PRIORITY JOURNAL; TUMOR LYSIS SYNDROME;

EID: 34249875952     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60903-9     Document Type: Letter

References (5)

1. Chow L., and Eckhardt S. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25 (2007) 884-896
2. Motzer R., Hutson T., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
3. Baeksgaard L., and Sorensen J. Acute tumor lysis syndrome in solid tumors-a case report and review of the literature. Cancer Chemother Pharmacol 51 (2003) 187-192
4. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 (2006) 660-664
5. Rini B., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 (2007) 81-83